Cargando…

Drugging the “undruggable” DNA-binding domain of STAT3

Detalles Bibliográficos
Autores principales:	Zhang, Jian-Ting, Liu, Jing-Yuan
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Impact Journals LLC 2016
Materias:	Editorial
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5341805/ https://www.ncbi.nlm.nih.gov/pubmed/27661130 http://dx.doi.org/10.18632/oncotarget.12181

Ejemplares similares

Targeting STATs for cancer therapy: “Undruggable” no more
por: Frank, David A.
Publicado: (2012)

Targeting allosteric regulatory modules in oncoproteins: “Drugging the Undruggable”
por: Hantschel, Oliver, et al.
Publicado: (2011)

Drugging an undruggable pocket on KRAS
por: Kessler, Dirk, et al.
Publicado: (2019)

Drugging the Undruggable: Advances on RAS Targeting in Cancer
por: Molina-Arcas, Miriam, et al.
Publicado: (2021)

Drugging the undruggables: exploring the ubiquitin system for drug development
por: Huang, Xiaodong, et al.
Publicado: (2016)

The Future of Medicinal Chemistry, PROTAC, and Undruggable Drug Targets
por: Poso, Antti
Publicado: (2021)

Drugging the undruggable: Ross Cagan interviews Kevan Shokat
por: Cagan, Ross, et al.
Publicado: (2022)

Drugging the Undruggable Trypanosoma brucei Monothiol Glutaredoxin 1
por: Favaro, Annagiulia, et al.
Publicado: (2023)

Therapeutic targeting of “undruggable” MYC
por: Llombart, Victor, et al.
Publicado: (2021)

KRAS G12C mutation: from undruggable target to potentially agnostic biomarker
por: El Osta, Badi
Publicado: (2023)

A Small Molecule Compound Targeting STAT3 DNA-Binding Domain Inhibits Cancer Cell Proliferation, Migration, and Invasion
por: Huang, Wei, et al.
Publicado: (2014)

Penetrating the central nervous system sanctuary of KRAS, a target once thought “undruggable”
por: Nagasaka, Misako, et al.
Publicado: (2023)

Recent advances in targeting the “undruggable” proteins: from drug discovery to clinical trials
por: Xie, Xin, et al.
Publicado: (2023)

KRAS mutation: from undruggable to druggable in cancer
por: Huang, Lamei, et al.
Publicado: (2021)

Targeting the undruggable oncogenic KRAS: the dawn of hope
por: Asimgil, Hande, et al.
Publicado: (2022)

Targeted Protein Degradation: An Important Tool for Drug Discovery for “Undruggable” Tumor Transcription Factors
por: Dai, Mengyuan, et al.
Publicado: (2022)

Targeting the “undruggable” RAS - new strategies - new hope?
por: Mörchen, Britta, et al.
Publicado: (2019)

Mitogen-Activated Protein Kinase Phosphatases: No Longer Undruggable?
por: Shillingford, Shanelle R., et al.
Publicado: (2023)

Emerging Pharmacotherapeutic Strategies to Overcome Undruggable Proteins in Cancer
por: Lu, Yuqing, et al.
Publicado: (2023)

Drugging the undruggable: activity-based protein profiling offers opportunities for targeting the KLK activome
por: Lee, Kristi Y., et al.
Publicado: (2022)

Big data and artificial intelligence discover novel drugs targeting proteins without 3D structure and overcome the undruggable targets
por: He, Huiqin, et al.
Publicado: (2020)

Novel STAT3 Inhibitors Targeting STAT3 Dimerization by Binding to the STAT3 SH2 Domain
por: Hua, Yaping, et al.
Publicado: (2022)

Commentary: PROTACs make undruggable targets druggable: Challenge and opportunity
por: Lu, Bin, et al.
Publicado: (2021)

MMPP Attenuates Non-Small Cell Lung Cancer Growth by Inhibiting the STAT3 DNA-Binding Activity via Direct Binding to the STAT3 DNA-Binding Domain
por: Son, Dong Ju, et al.
Publicado: (2017)

The Unpluggable in Pursuit of the Undruggable: Tackling the Dark Matter of the Cancer Therapeutics Universe
por: Epstein, Richard J.
Publicado: (2013)

Chemically Induced Cellular Proteolysis: An Emerging Therapeutic Strategy for Undruggable Targets
por: Moon, Seonghyeon, et al.
Publicado: (2018)

Targeting the undruggable: an interview with Leila Akkari on fighting cancer by rewiring cells
Publicado: (2021)

Targeting the ‘Undruggable’ Driver Protein, KRAS, in Epithelial Cancers: Current Perspective
por: Lam, Kuen Kuen, et al.
Publicado: (2023)

MicroRNA-708 emerges as a potential candidate to target undruggable NRAS
por: Pang, Jia Meng, et al.
Publicado: (2023)

Novel Synthetic bisindolylmaleimide alkaloids inhibit STAT3 activation by binding to the SH2 domain and suppress breast xenograft tumor growth
por: Li, Xia, et al.
Publicado: (2018)

Covalent inhibitor targets KRas(G12C): A new paradigm for drugging the undruggable and challenges ahead
por: Li, Hui-yu, et al.
Publicado: (2021)

Rational antibody design for undruggable targets using kinetically controlled biomolecular probes
por: Trkulja, Carolina L., et al.
Publicado: (2021)

Targeting undruggable carbohydrate recognition sites through focused fragment library design
por: Shanina, Elena, et al.
Publicado: (2022)

ATNC: Versatile Nanobody Chimeras for Autophagic Degradation of Intracellular Unligandable and Undruggable Proteins
por: He, Huiping, et al.
Publicado: (2023)

A short deletion in the DNA-binding domain of STAT3 suppresses growth and progression of colon cancer cells
por: Xiong, Yi-Jia, et al.
Publicado: (2021)

Targeting the undruggable: exploiting neomorphic features of fusion oncoproteins in childhood sarcomas for innovative therapies
por: Knott, Maximilian M. L., et al.
Publicado: (2020)

The Fra-1/AP-1 Oncoprotein: From the “Undruggable” Transcription Factor to Therapeutic Targeting
por: Casalino, Laura, et al.
Publicado: (2022)

A New Wave of Targeting ‘Undruggable’ Wnt Signaling for Cancer Therapy: Challenges and Opportunities
por: Park, Woo-Jung, et al.
Publicado: (2023)

Design of rigid protein–protein interaction inhibitors enables targeting of undruggable Mcl-1
por: Hargreaves, David, et al.
Publicado: (2023)

Targeting STAT3 and STAT5 in Cancer
por: de Araujo, Elvin D., et al.
Publicado: (2020)

Cannot write session to /tmp/vufind_sessions/sess_j4o6f6q7f9u26lfk3hf6aqe9ne